Company Filing History:
3 out of 15,515 
2 out of 2 
1 out of 141 
Years Active: 2018-2020
Title: Inventor Spotlight: Clare L M LeGuyader
Introduction
Clare L M LeGuyader, based in San Diego, California, is a notable inventor recognized for his contributions to cancer treatment through innovative compounds. With three patents to his name, LeGuyader has made significant strides in the field of medical research, particularly in the development of modified cytotoxins.
Latest Patents
Among his most recent patented innovations is the work on "Modified Cytotoxins and Their Therapeutic Use". This patent presents compounds designed to treat cancer effectively. The disclosure reveals small-molecule cytotoxins that are chemically modified to incorporate hydrophobic portions. In various embodiments, these cytotoxins include fatty acid-containing moieties, enhancing their therapeutic effectiveness. Additionally, the patent discusses pharmaceutical compositions that comprise these modified small-molecule cytotoxins along with proteins, specifically highlighting albumin or albumin mimetics.
Career Highlights
Clare has worked with esteemed institutions such as the University of California and Vybyl Holdings, Inc., where he has leveraged his expertise to advance research in pharmacology and therapeutics. His work showcases a blend of scientific knowledge and innovation aimed at addressing critical health challenges.
Collaborations
Throughout his career, Clare L M LeGuyader has had the opportunity to collaborate with talented individuals, including his coworkers Cassandra E Callmann and Matthew P Thompson. These collaborations have played a crucial role in enhancing the impact of his research and the development of new therapeutic strategies.
Conclusion
Clare L M LeGuyader's innovative contributions to the medical field, particularly in cancer treatment, exemplify the important role of inventors in healthcare advancements. His patents not only reflect his dedication but also promise significant benefits for patients in need of effective therapies. Through ongoing research and collaboration, LeGuyader continues to pave the way for future breakthroughs in medical science.